Ryan Allway August 2nd, 2019 Exclusive, News, Top Story, Uncategorized Only days after announcing that its wholly owned subsidiary was awarded a German cannabis... XPhyto Therapeutics Ready to Be Cannabis’ Newest Public Entity

Ryan Allway

August 2nd, 2019

Exclusive, News, Top Story, Uncategorized


Only days after announcing that its wholly owned subsidiary was awarded a German cannabis and cultivation and extraction licence, XPhyto Therapeutics is ready to enter the public domain. With a final prospectus filed with the British Columbia Securities Commission, XPhyto is ready to go public on the CSE under the ticker “XPHY”. The company will begin trading on the CSE on Tuesday, August 6, 2019.

Dual Market Focus: Germany

From its corporate headquarters in Vancouver, XPhyto is developing its business as a leader in formulation, processing, and clinical validation in two of the world’s most active markets, Canada and Germany. Germany, the largest economy in the European Union and second largest federally regulated medical cannabis market in the world (behind the U.S.), is seeing tremendous acceleration in cannabis demand, including importing nearly 2,500 kilograms for medical purposes in the first half of 2019. That’s almost as much as was imported in all of 2018 and more than twice as much as 2017.

Germany Flag on cannabis background. Drug policy. Legalization of marijuana

Click here to receive an investor deck and going public alert

Right now, Germany relies 100% on imports to supply is burgeoning medical cannabis market. Based upon some recently issued licenses, it will be until at least late in 2020 before any domestic cannabis will be available for medical purposes.

It is this growth that underscores Arcview Market Research forecasting Germany’s cannabis market to experience a whopping 76.8% compound annual growth rate to reach $1.6 billion by 2022.

Last Wednesday, the Company announced that its wholly owned German subsidiary, Bunker Pflanzenextrakte GmbH, was awarded a cannabis cultivation and extraction licence for scientific purposes from the German Federal Institute for Drugs and Medical Devices, better known as BfArM. Bunker still has to pass BfArM’s security requirements, which isn’t expected to be an issue considering the company operates from a monitored high-security area in Bavaria that previously served as a German air force command center and nuclear bunker.

Bunker has a long-term lease for the entire facility with 10,741 square feet for the initial buildout and nearby space available for expansion.

The new licence authorizes Bunker to cultivate and extract up to 70 different strains of cannabis sativa and indica for scientific R&D.

With the new licence in tow, Bunker is next applying for licenses that will allow for cannabis import, storage, distribution and manufacturing. The license estate is at the heart of Bunker’s plans to serve as a one-stop shop providing a bevy of products and services spanning genetic research and storage, cultivation, extraction, storage, processing, packaging, distribution and more.

Click here to receive an investor deck and going public alert

Dual Market Focus: Canada

Canada made history last year when it became the first G7 country to legalize adult-use marijuana. Supply shortages and regulatory challenges kept the industry from getting off to the rip-roaring start analysts expected, but that hasn’t stopped Arcview Market Research and partner BDS Analytics from forecasting the Canadian cannabis market reaching $5.2 billion by 2024.

XPhyto’s operations in Canada are centered on in-house production of pharmaceutical-grade cannabis-derived compounds, developing proprietary formulas and conducting modern clinical research for diseases and conditions with unmet medical need where cannabis could be a viable option. They also offer third-party commercial analytical testing for licensed producers, wholesalers, distributors and law enforcement.

Management is advancing these operations through strategic collaborations that accelerate the process with other collateral benefits. For instance, XPhyto has two five-year agreements with the University of Alberta’s Faculty of Pharmacy and Pharmaceutical Sciences. This partnership provides XPhyto with certified analytical testing capability, as well as a certified extraction, isolation, and formulation facility.

Click here to receive an investor deck and going public alert

This is a tremendous capital saver for XPhyto as its cost to entry pales in comparison to the value of the world-class infrastructure, not to mention potential maintenance costs in the future. Furthermore, The University of Alberta is well known for its expertise in biopharmaceutics, drug delivery quality control and regulatory sciences.  An authority like that as a strategic partner gives XPhyto immediate brand recognition as a high quality service provider and access to talent that other companies simply do not easily come by.

Public Soon

XPhyto is hitting the ground running when it comes public as it looks to fill a void between cannabis and modern medical science. They have secured a collaborative partner in the esteemed experts at the University of Alberta to capitalize on the opportunity with minimal capex while the Bunker acquisition – along with its assets – give XPhyto a first mover advantage in the burgeoning German market.

XPhyto will commence trading on the CSE on Tuesday, August 6, 2019, which should have investors keen to participate in the next wave of cannabis opportunities – medical formulations and emerging European markets.

Click here to receive an investor deck and going public alert

Disclaimer

CannabisFN.com is not an independent financial investment advisor or broker-dealer. You should always consult with your own independent legal, tax, and/or investment professionals before making any investment decisions. The information provided on https://www.cannabisfn.com (the ‘Site’) is either original financial news or paid advertisements drafted by our in-house team or provided by an affiliate. CannabisFN.com, a financial news media and marketing firm enters into media buys or service agreements with the companies that are the subject of the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider. We make no warranty or representation about the information including its completeness, accuracy, truthfulness or reliability and we disclaim, expressly and implicitly, all warranties of any kind, including whether the Information is complete, accurate, truthful, or reliable. As such, your use of the information is at your own risk. Nor do we undertake any obligation to update the items posted. CannabisFN.com received compensation for producing and presenting high quality and sophisticated content on CannabisFN.com along with financial and corporate news.

Ryan Allway

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


MJ Shareholders avatar

MJ Shareholders

MJShareholders.com is the largest dedicated financial network and leading corporate communications firm serving the legal cannabis industry. Our network aims to connect public marijuana companies with these focused cannabis audiences across the US and Canada that are critical for growth: Short and long term cannabis investors Active funding sources Mainstream media Business leaders Cannabis consumers

( ) ( ) ( ) ( ) ( ) ( ) ( ) ( )